Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PUMA BIOTECHNOLOGY, INC.

(PBYI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/19/2021 10/20/2021 10/21/2021 10/22/2021 10/25/2021 Date
5.93(c) 5.91(c) 5.89(c) 5.69(c) 5.27(c) Last
232 410 363 134 286 442 307 017 1 077 438 Volume
+0.17% -0.34% -0.34% -3.40% -7.38% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 264 M - -
Net income 2021 -1,73 M - -
Net cash position 2021 54,2 M - -
P/E ratio 2021 -19,3x
Yield 2021 -
Sales 2022 255 M - -
Net income 2022 -8,55 M - -
Net cash position 2022 54,7 M - -
P/E ratio 2022 -11,5x
Yield 2022 -
Capitalization 215 M 215 M -
EV / Sales 2021 0,61x
EV / Sales 2022 0,63x
Nbr of Employees 267
Free-Float 86,6%
More Financials
Company
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to improve cancer care. The Company's products include PB272 (neratinib, oral), PB272 (neratinib, intravenous), and PB357, as well as certain related compounds. Its lead product, NERLYNX, is an oral version of neratinib, which is a potent irreversible tyrosine kinase inhibitor (TKI),... 
More about the company
Ratings of Puma Biotechnology, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about PUMA BIOTECHNOLOGY, INC.
10/21PUMA BIOTECHNOLOGY : to Host Conference Call to Discuss Third Quarter Financial Results
BU
10/18CELCUITY : Unveils Partnership for Phase 2 Trial of Combination Treatment Targeting Breast..
MT
10/18Celcuity Inc. Announces Clinical Trial Collaboration with University of Rochester Wilmo..
CI
10/06PUMA BIOTECHNOLOGY : Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
BU
09/28PUMA BIOTECHNOLOGY : Citigroup Upgrades Puma Biotechnology to Buy From Neutral, Price Targ..
MT
09/21PUMA BIOTECHNOLOGY : to Present at the Cantor Virtual Global Healthcare Conference
BU
09/20PUMA BIOTECHNOLOGY, INC.(NASDAQGS : PBYI) dropped from S&P Biotechnology Select Industry I..
CI
09/07PUMA BIOTECHNOLOGY : Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
BU
09/07PUMA BIOTECHNOLOGY : to Present at the H.C. Wainwright 23rd Annual Global Investment Confe..
BU
08/06PUMA BIOTECHNOLOGY : Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
BU
08/06PUMA BIOTECHNOLOGY : RBC Cuts PT on Puma Biotechnology to $6 From $13, Citing Nerlynx 2021..
MT
08/05PUMA BIOTECH : Q2 Earnings Snapshot
AQ
08/05PUMA BIOTECHNOLOGY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
08/05PUMA BIOTECHNOLOGY : Reports Second Quarter 2021 Financial Results
BU
08/05PUMA BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
More news
News in other languages on PUMA BIOTECHNOLOGY, INC.
03/05Polyphor schliesst 2020 mit einem Verlust von knapp 45 Millionen Franken ab
03/05EQS-ADHOC : Polyphor gibt Finanzergebnis für das -2-
02/27PUMA BIOTECHNOLOGY : und Pierre Fabre ändern die NERLYNX«-Lizenzvereinbarung, die neu auch..
02/25PUMA BIOTECHNOLOGY : et Pierre Fabre amendent leur accord de licence NERLYNX« pour y inclu..
2019PUMA BIOTECHNOLOGY : und Pierre Fabre schließen exklusiven Lizenzvertrag zur Entwicklung u..
More news
Analyst Recommendations on PUMA BIOTECHNOLOGY, INC.
More recommendations
Chart PUMA BIOTECHNOLOGY, INC.
Duration : Period :
Puma Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PUMA BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Last Close Price 5,27 $
Average target price 8,43 $
Spread / Average Target 59,9%
EPS Revisions
Managers and Directors
Alan H. Auerbach Chairman, President, CEO & Secretary
Maximo F. Nougues Chief Financial Officer
Jay M. Moyes Lead Independent Director
Troy E. Wilson Independent Director
Adrian M. Senderowicz Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PUMA BIOTECHNOLOGY, INC.-48.64%215
MODERNA, INC.234.60%141 099
LONZA GROUP AG31.93%60 646
IQVIA HOLDINGS INC.43.58%49 145
SEAGEN INC.0.22%31 933
CELLTRION, INC.-39.69%25 328